Dr. Klumper is a life science entrepreneur and combines a scientific and business background holding a MD and PhD in medicine and an international MBA. He is co-founder/owner of iClusion Ltd - an internet platform company recruiting cancer patients for clinical studies, and co-founder/owner of SMS-oncology Ltd - an oncology contract research organization. Prior he has served as acting CMO at several biotechnology companies, Vice-President Marketing & Sales Europe at Nabi Biopharmaceuticals, European Brand Director at Amgen, Business Unit Director at Amgen in The Netherlands and in the United Kingdom. Cancer research and development is his field of expertise. With 25 years of experience, he has been involved in the European launch of a block buster drug, has successfully turned around a company, and has supervised 80 cancer drug development programs and 20 clinical studies.
Torbjørn Furuseth, MD, CFO and acting CBO
Employed since 2017
Dr. Furuseth has broad experience from most aspects within life sciences sector. Before joining Lytix Biopharma he was in the executive management team at Aker BioMarine responsible for Innovation, including science documentation, product development patent prosecution and litigation. He also has experience from sales processes, due diligence, negotiations and transactions in life sciences. Dr. Furuseth has six years of experience as management consultant at McKinsey & Co serving clients within the Pharma and Health Care practice on commercial, operational and strategic topics.
Dr. Furuseth obtained his medical degree at Norwegian University of Science and Technology in 2004, and have three years of clinical practice.
Hamina Patel, MB BCh MSc MRCPI, CMO
Employed since 2018
Dr Patel is a physician and C level pharmaceutical executive with over 18 years of experience with a proven track record of leadership, having successfully led large global teams within Pharma and Biotech. Previous Managing Director of StratiPhy Consulting Ltd providing strategic expertise to the pharmaceutical, biotech and venture industry. Past accomplishments include successfully obtaining global MAA for VELCADE in MCL, the first single agent approval for this indication, being integral to the successful launch of the Oncology franchise at Johnson and Johnson and serving as their Oncology CREDO champion for 3 years.
Dr Patel has her MB BCh, Bachelor of Medicine and Bachelor of Surgery, from the University of Wales, College of Medicine.
Øystein Rekdal, PhD, Head R&D and CSO
Employed since 2003
Dr. Rekdal is co-founder of Lytix Biopharma and has extensive research background within tumor immunology, oncolytic peptides and their abilities to induce potent tumor specific immune responses. Dr. Rekdal commenced his PhD on cytokines and tumor immunology in 1996. His postdoctoral work was focusing on oncolytic peptides and their abilities to induce potent tumor specific immune responses. This research forms the basis of Lytix Biopharma’s oncolytic peptide platform. Dr. Rekdal is leading the collaboration with several distinguished researchers and institutions to further explore the unique ability of oncolytic peptides to reprogram non-inflamed or suppressive in experimental models and in cancer patients. He also serves as a visiting professor at the University of Tromsø, Norway.